1 month ago
Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function.
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.
#revenue #NASDAQ #joenja #pediatric
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.
#revenue #NASDAQ #joenja #pediatric
1 month ago
Tesla, Inc. (NASDAQ:TSLA) spent nearly two years raising anticipation for the Cybercab. When the time arrived on September 3 in Austin, the result was a stock that popped, then rapidly returned all of its gains, and a robotaxi race that still seems to be Alphabet's to lose.
Tesla, Inc. (NASDAQ:TSLA) had its long-awaited Cybercab launch event in Austin, Texas, but it was invitation-only, not livestreamed, and CEO Elon Musk wasn't there. The company's main public update was a 51-second video released on X of the two-seat, steering-wheel-free vehicle roaming city streets and people hailing it by app. Shares rose roughly 5% throughout the session, finishing near $376. By September 4, enthusiasm had waned, with the stock plummeting as much as 6% as investors realized how little the event revealed about deployment timelines, production ramp, or regulatory clearance.
Only 45 Cybercabs were registered in Texas, and Tesla, Inc. (NASDAQ:TSLA) did not seek an NHTSA exemption before deployment, instead self-certifying the Cybercab as compliant with applicable federal safety standards. NHTSA subsequently opened an audit into that certification and has ordered Tesla to provide additional information about the basis for its compliance claims. CNBC summarized the reaction bluntly: the update "underwhelmed" Wall Street, which had been relying on Tesla, Inc. (NASDAQ:TSLA) becoming a strong rival in the robotaxi sector, which Alphabet's Waymo currently leads.
That comparison is at the heart of the story. Waymo has established the operational track record that Tesla, Inc. (NASDAQ:TSLA) is still chasing: more than 4,000 autonomous vehicles across its U.S. fleet and more than 500,000 fully autonomous rides per week.
Wall Street's take on the incident was severely divided along those lines. Despite Tesla's efforts to control the narrative, some ******* ysts, including Gary Black of Future Fund, called the Cybercab debut largely a bust. Others, such as Deepwater ******* et Management's Gene Munster, predicted that Tesla, Inc. (NASDAQ:TSLA) will add approximately 300 Cybercabs in Austin over the next month.
#tesla #NASDAQ #cybercab
Tesla, Inc. (NASDAQ:TSLA) had its long-awaited Cybercab launch event in Austin, Texas, but it was invitation-only, not livestreamed, and CEO Elon Musk wasn't there. The company's main public update was a 51-second video released on X of the two-seat, steering-wheel-free vehicle roaming city streets and people hailing it by app. Shares rose roughly 5% throughout the session, finishing near $376. By September 4, enthusiasm had waned, with the stock plummeting as much as 6% as investors realized how little the event revealed about deployment timelines, production ramp, or regulatory clearance.
Only 45 Cybercabs were registered in Texas, and Tesla, Inc. (NASDAQ:TSLA) did not seek an NHTSA exemption before deployment, instead self-certifying the Cybercab as compliant with applicable federal safety standards. NHTSA subsequently opened an audit into that certification and has ordered Tesla to provide additional information about the basis for its compliance claims. CNBC summarized the reaction bluntly: the update "underwhelmed" Wall Street, which had been relying on Tesla, Inc. (NASDAQ:TSLA) becoming a strong rival in the robotaxi sector, which Alphabet's Waymo currently leads.
That comparison is at the heart of the story. Waymo has established the operational track record that Tesla, Inc. (NASDAQ:TSLA) is still chasing: more than 4,000 autonomous vehicles across its U.S. fleet and more than 500,000 fully autonomous rides per week.
Wall Street's take on the incident was severely divided along those lines. Despite Tesla's efforts to control the narrative, some ******* ysts, including Gary Black of Future Fund, called the Cybercab debut largely a bust. Others, such as Deepwater ******* et Management's Gene Munster, predicted that Tesla, Inc. (NASDAQ:TSLA) will add approximately 300 Cybercabs in Austin over the next month.
#tesla #NASDAQ #cybercab
1 month ago
Interested in Johnson & Johnson? Here are five stocks we like better.
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Executives see 2027 improving further and aim for double-digit growth by the end of the decade despite STELARA biosimilar competition.
The company plans to detail its long-term growth strategy at an enterprise review in December, highlighting new product launches, a pipeline that includes 12 proof-of-concept molecules in Phase III, and the durability of growth beyond 2030.
Capital spending is focused on Innovative Medicine and MedTech launches, including ICOTYDE, cancer treatments, and the OTTAVA robotic surgical system. J&J also expects continued momentum from its myeloma therapies, ICOTYDE's expanding coverage, and MedTech products, while using acquisitions mainly to support growth beyond the current decade.
5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
#adjusted #interested
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Executives see 2027 improving further and aim for double-digit growth by the end of the decade despite STELARA biosimilar competition.
The company plans to detail its long-term growth strategy at an enterprise review in December, highlighting new product launches, a pipeline that includes 12 proof-of-concept molecules in Phase III, and the durability of growth beyond 2030.
Capital spending is focused on Innovative Medicine and MedTech launches, including ICOTYDE, cancer treatments, and the OTTAVA robotic surgical system. J&J also expects continued momentum from its myeloma therapies, ICOTYDE's expanding coverage, and MedTech products, while using acquisitions mainly to support growth beyond the current decade.
5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
#adjusted #interested
2 months ago
On September 3, Genesco (NYSE:GCO) reported a second quarter that should not have worked on paper. Revenue fell 3% to $530 million, yet the company nearly halved its adjusted operating loss and raised full-year earnings guidance to the top end of its range. That combination, shrinking sales alongside expanding profit, is the footwear-first strategy showing up in real numbers. Every one of the company's three brands beat internal expectations, and management says the toughest sales pressure ahead is coming from a deliberate choice rather than a weakening business.
Journeys, the company's teen-focused chain, delivered its eighth consecutive quarter of positive comparable sales, up 2%, even while lapping strong growth from a year earlier. The more interesting story sits underneath that number. The Journeys 4.0 store format, a redesigned concept built around a more elevated ***** ortment, is generating a sales lift of 25% or more wherever it opens, and the company expects roughly 180 locations, about a fifth of its fleet, running that format by year-end. That rollout, combined with fleet optimization and more efficient use of selling staff, handed Journeys 180 basis points of expense leverage in the quarter. Comparable sales kept accelerating into August, marking Journeys' ninth straight month of positive comps and a mid-single-digit gain during the back-to-school peak.
Johnston & Murphy is running its own streak, with comparable sales up 4% in its third consecutive positive quarter, helped by a newly extended, multiyear partnership with Peyton Manning and a broader shift in menswear toward more refined, put-together dressing. Companywide, adjusted gross margin expanded 140 basis points to 47.2%, and the adjusted operating loss narrowed to $8 million from $14 million a year ago. Genesco also collected $22.5 million in tariff refunds during the quarter and cut total debt to $15.8 million from $71 million a year earlier, giving a new CFO and a new Schuh president a far healthier balance sheet to work with as they settle into their roles.
The drag comes almost entirely from Schuh, Genesco's UK chain, where comparable sales fell 9% as management deliberately pulled back on discounting to protect margin. Executives were blunt about the cost of that choice. CEO Mimi Vaughn said "the UK consumer market remains challenged and price sensitive," and the Schuh turnaround is expected to take longer than the one already underway at Journeys. That pressure is now baked into guidance. Full-year total sales are expected to fall about 2%, worse than the prior forecast of down 1% to flat, with management incorporating more back-half sales pressure than it originally planned for given how promotional the UK footwear market has become.
#comparable #schuh #management #pressure
Journeys, the company's teen-focused chain, delivered its eighth consecutive quarter of positive comparable sales, up 2%, even while lapping strong growth from a year earlier. The more interesting story sits underneath that number. The Journeys 4.0 store format, a redesigned concept built around a more elevated ***** ortment, is generating a sales lift of 25% or more wherever it opens, and the company expects roughly 180 locations, about a fifth of its fleet, running that format by year-end. That rollout, combined with fleet optimization and more efficient use of selling staff, handed Journeys 180 basis points of expense leverage in the quarter. Comparable sales kept accelerating into August, marking Journeys' ninth straight month of positive comps and a mid-single-digit gain during the back-to-school peak.
Johnston & Murphy is running its own streak, with comparable sales up 4% in its third consecutive positive quarter, helped by a newly extended, multiyear partnership with Peyton Manning and a broader shift in menswear toward more refined, put-together dressing. Companywide, adjusted gross margin expanded 140 basis points to 47.2%, and the adjusted operating loss narrowed to $8 million from $14 million a year ago. Genesco also collected $22.5 million in tariff refunds during the quarter and cut total debt to $15.8 million from $71 million a year earlier, giving a new CFO and a new Schuh president a far healthier balance sheet to work with as they settle into their roles.
The drag comes almost entirely from Schuh, Genesco's UK chain, where comparable sales fell 9% as management deliberately pulled back on discounting to protect margin. Executives were blunt about the cost of that choice. CEO Mimi Vaughn said "the UK consumer market remains challenged and price sensitive," and the Schuh turnaround is expected to take longer than the one already underway at Journeys. That pressure is now baked into guidance. Full-year total sales are expected to fall about 2%, worse than the prior forecast of down 1% to flat, with management incorporating more back-half sales pressure than it originally planned for given how promotional the UK footwear market has become.
#comparable #schuh #management #pressure
